Filtern
Dokumenttyp
Sprache
- Englisch (2)
Referierte Publikation
- ja (2)
Schlagworte
- Hyperthermia (1)
- Ionic liquid (1)
- Iron carbide (1)
- Iron oxide (1)
- MRI (1)
- Nanoparticle (1)
- Theranostics (1)
Organisationseinheit der BAM
Dispersions of Fe3C nanoparticles in several ionic liquids (ILs) have been investigated. The ILs are based on 1-ethyl-3-methylimidazolium [Emim] and 1-butyl-3-methylimidazolium [Bmim] cations. Anions are ethylsulfate [ES], methanesulfonate [MS], trifluoromethylsulfonate (triflate) [TfO], tetrafluoroborate [BF4], dicyanamide [N(CN)2], and thiocyanate [SCN]. Among the ILs studied, [Emim][SCN] and [Emim][N(CN)2] stand out because only in these ILs have stable and transparent nanoparticle dispersions been obtained. All other ILs lead to blackish, slightly turbid dispersions or to completely nontransparent suspensions, which often contain undispersed sediment. UV/vis spectroscopy, transmission electron microscopy, and X-ray scattering suggest that the reason for the stabilization of the Fe3C nanoparticles in [Emim][SCN] is the leaching of traces of iron from the particles (without affecting the crystal structure of the Fe3C particles). The resulting particle surface is thus carbon-rich, which presumably favors the stabilization of the particles. A similar explanation can be postulated for [Emim][N(CN)2], with the dicyanamide anion also being a good ligand for iron.
Iron oxide nanoparticles are a promising platform for biomedical applications, both in terms of diagnostics and therapeutics. In addition, arginine-rich polypeptides are known to penetrate across cell membranes. Here, we thus introduce a system based on magnetite nanoparticles and the polypeptide poly-l-arginine (polyR-Fe3O4). We show that the hybrid nanoparticles exhibit a low cytotoxicity that is comparable to Resovist®, a commercially available drug. PolyR-Fe3O4 particles perform very well in diagnostic applications, such as magnetic particle imaging (1.7 and 1.35 higher signal respectively for the 3rd and 11th harmonic when compared to Resovist®), or as contrast agents for magnetic resonance imaging (R2/R1 ratio of 17 as compared to 11 at 0.94 T for Resovist®). Moreover, these novel particles can also be used for therapeutic purposes such as hyperthermia, achieving a specific heating power ratio of 208 W/g as compared to 83 W/g for Feridex®, another commercially available product. Therefore, we envision such materials to play a role in the future theranostic applications, where the arginine ability to deliver cargo into the cell can be coupled to the magnetite imaging properties and cancer fighting activity.